synthesi
preliminari
vitro
activ
monoand
blactamisatin
conjug
human
protozo
pathogen
trichomona
vaginali
abstract
studi
describ
synthesi
monoand
blactamisatin
conjug
use
coppercatalys
azidealkyn
cycloaddit
reaction
monoand
dipropargyl
nalkylazido
isatin
synthes
conjug
evalu
preliminari
vitro
analysi
trichomona
vaginali
lm
efficaci
synthes
hybrid
observ
depend
substitu
posit
blactam
ring
well
presenc
singledoubl
linker
among
synthes
conjug
presenc
ptolyl
substitu
blactam
ring
prefer
good
activ
profil
increas
spacer
length
influenc
efficaci
compound
compound
high
level
potenc
analys
determin
ic
valu
well
cytotox
profil
mammalian
cell
activ
compound
synthes
conjug
display
ic
valu
lm
cultur
strain
vaginali
nontox
cultur
mammalian
hela
cell
concentr
approxim
million
new
case
occur
worldwid
annual
geneva
human
trichomoniasi
far
preval
sexual
transmit
diseas
std
either
chlamydia
caus
chlamydia
trachomati
gonorrhoea
caus
neisseria
gonorrhoea
soper
caus
organ
diseas
human
trichomona
vaginali
primarili
acquir
transmiss
trophozoit
direct
sexual
contact
although
neonat
infect
also
report
mclaren
et
al
metronidazol
mtz
current
fdaapprov
treatment
diseas
use
year
howev
ampl
report
develop
resist
isol
mtz
certain
case
shown
tackl
prolong
therapi
higher
dosag
wright
et
al
upcroft
et
al
entrench
trichomoniasisinfect
patient
suscept
toward
human
immunodefici
viru
hiv
appear
cofactor
hiv
transmiss
acquisit
sorvillo
et
al
van
der
pol
et
al
signific
increas
vulner
hiv
trichomoniasi
mcclelland
et
al
guenthner
et
al
increas
import
diseas
dramat
evid
identif
develop
novel
scaffold
toxic
vaginali
minim
cytotox
human
cell
challeng
task
provid
strong
impetu
reengin
reposit
previous
character
drug
famili
upcroft
et
al
onlin
version
articl
contain
supplementari
materi
avail
author
user
isatin
privileg
scaffold
well
toler
human
analogu
demonstr
divers
rang
biolog
pharmacolog
properti
antihiv
bal
et
al
antivir
quenel
et
al
anticanc
vine
lock
kopka
et
al
antifung
raj
et
al
anticonvuls
verma
et
al
antiparkinson
diseas
therapeut
igosheva
et
al
blactamas
inhibitor
casey
et
al
hadfield
et
al
effect
sar
coronaviru
proteas
inhibitor
chen
et
al
enthral
applic
isatin
organ
synthesi
biolog
properti
well
occurr
natur
product
spirotryprostatin
horsfilin
gelsemin
gelseverin
rhynchophyllin
elacomin
etc
gener
tremend
interest
among
synthet
organ
medicin
chemist
fensom
et
al
kumari
et
al
ding
et
al
vintonyak
et
al
rottmann
et
al
particular
exampl
deriv
semaxanib
sunitinib
report
tyrosin
kinas
inhibitori
antiangiogen
properti
et
al
prenen
et
al
blactam
crucial
structur
unit
present
wide
blactam
class
antibiot
palomo
et
al
palomo
et
al
follow
discoveri
penicillin
array
natur
occur
blactam
antibiot
introduc
chemotherapeut
incompar
effect
treatment
bacteri
infect
current
interest
famili
focus
synthesi
modif
blactam
ring
obtain
compound
divers
pharmacolog
potenti
tumour
necrosi
factoralpha
tnfalpha
convert
enzym
tace
inhibitor
rao
et
al
anticanc
oboyl
et
al
singh
et
al
anticoccidi
liang
et
al
cardiovascular
takai
et
al
takai
et
al
antivir
dhoogh
et
al
mutagen
gutierrez
et
al
antifung
odriscol
et
al
antimalari
activ
jarrahpour
et
al
besid
emin
heterocycl
system
numer
biolog
potenti
blactam
also
employ
synthet
precursor
synthesi
wide
varieti
heterocycl
scaffold
singh
alcaid
et
al
dhoogh
et
al
singh
et
al
recent
pharmacophor
hybrid
appear
attract
paradigm
medicin
chemist
main
incent
use
strategi
relat
mark
improv
therapeut
potenti
potenc
mode
action
pharmacokinet
meunier
muregi
ishih
morphi
rankov
continu
effort
synthesi
novel
molecular
conjug
biolog
potenti
raj
et
al
raj
et
al
nisha
et
al
kumar
et
al
kumar
et
al
recent
discuss
synthesi
blactamisatin
conjug
vitro
evalu
vaginali
raj
et
al
synthes
compound
exhibit
growth
inhibit
lm
potent
noncytotox
compound
fig
display
ic
valu
lm
present
commun
extens
approach
compris
synthesi
monoand
bifunct
hybrid
isatin
substitut
blactam
fig
preliminari
vitro
evalu
studi
vaginali
rational
behind
use
linker
activ
particip
hydrogen
bond
dipoledipol
interact
stabil
hydrolysi
oxidativereduct
condit
kolb
et
al
kolb
sharpless
wang
et
al
bock
et
al
melt
point
determin
open
capillari
use
veego
precis
digit
melt
point
apparatu
mpd
uncorrect
ir
spectra
record
shimadzu
spectrophotomet
h
nmr
spectra
record
deuterochloroform
dimethylsulphoxid
jeol
mhz
spectromet
use
tm
intern
standard
chemic
shift
valu
express
part
per
million
downfield
tm
j
valu
hertz
split
pattern
indic
singlet
doublet
triplet
multiplet
dd
doubl
doublet
ddd
doublet
doublet
doublet
br
broad
peak
c
nmr
spectra
record
jeol
mhz
spectromet
deuterochloroform
dimethylsulphoxid
use
tm
intern
standard
highresolut
mass
spectra
record
brukermicrotofq
ii
spectromet
column
chromatographi
perform
silica
gel
mesh
gener
method
prepar
blactamisatin
conjug
stir
solut
azid
mmol
mmol
ethanolwat
ad
success
appropri
acetylen
lactam
mmol
copper
fig
recent
disclos
potent
noncytotox
blactamisatin
conjug
sulphat
mmol
mmol
sodium
ascorb
mmol
room
temperatur
complet
monitor
tlc
water
ad
reaction
mixtur
extract
chloroform
combin
organ
layer
dri
anhydr
sodium
sulphat
concentr
reduc
pressur
result
crude
product
purifi
silica
gel
column
chromatographi
vitro
protozo
parasit
suscept
assay
protozo
parasit
cultur
h
perform
initi
suscept
screen
vaginali
compound
suspend
dmso
obtain
concentr
lm
aliquot
suspens
dilut
ml
tym
diamond
media
obtain
final
concentr
lm
h
cell
count
use
hemacytomet
cell
count
normal
dmso
control
order
allow
direct
comparison
averag
variou
trial
data
set
transform
use
prism
softwar
graphpad
take
log
drug
concentr
trial
input
transform
log
inhibitor
versu
responsevari
slope
regress
option
within
nonlinear
regress
constraint
set
forc
maximum
valu
top
minimum
valu
bottom
slope
left
variabl
determin
regress
perform
sampl
size
consist
independ
trial
carri
four
differ
day
account
possibl
variat
parasit
cultur
assay
perform
ml
cultur
tube
wt
dmso
control
tube
normal
effect
solvent
vitro
condit
ic
valu
activ
compound
determin
run
assay
increas
drug
concentr
lm
perform
regress
analysi
use
prism
softwar
graphpad
cytotox
evalu
potent
compound
librari
cultur
mammalian
cell
hela
cell
maintain
dulbecco
modifi
eagl
medium
contain
penicillinstreptomycin
foetal
bovin
serum
humifi
co
atmospher
doxorubicin
bleomycin
potent
compound
librari
ad
medium
cell
h
cultur
trypan
blue
assay
use
h
drug
treatment
calcul
cell
viabil
done
three
separ
trial
ensur
cytotox
result
consist
accuraci
cytotox
assay
valid
use
etoposid
posit
control
exhibit
ic
valu
lm
compar
report
valu
travelli
et
al
monoand
dipropargyl
precursor
prepar
via
recent
report
protocol
involv
treatment
singh
et
al
mmol
propargyl
bromid
respect
treatment
mmol
propargyl
bromid
led
mixtur
ratio
evidenc
h
nmr
analysi
crude
reaction
mixtur
use
mmol
propargyl
bromid
result
isol
exclus
dipropargyl
product
observ
coupl
constant
j
hz
h
h
confirm
cisstereochemistri
product
scheme
nalkyl
azido
isatin
anoth
precursor
requir
synthesi
target
scaffold
prepar
initi
baseassist
nalkyl
isatin
dibromoalkan
follow
subsequ
reaction
sodium
azid
dmf
scheme
synthes
precursor
util
synthesi
desir
monoand
blactamisatin
conjug
thu
reaction
mmol
presenc
copper
sulphat
sodium
ascorb
ethanolwat
mixtur
led
isol
scheme
reaction
mmol
similar
condit
led
format
good
excel
yield
scheme
structur
hybrid
assign
basi
spectral
data
analyt
evid
compound
exampl
show
molecular
ion
peak
along
characterist
peak
h
c
nmr
spectra
vitro
activ
vaginali
synthes
monoand
blactamisatin
conjug
evalu
inhibitori
influenc
axen
vitro
growth
vaginali
strain
cultur
tym
diamond
media
h
tabl
list
data
obtain
initi
percentag
inhibit
screen
lm
evid
tabl
activ
profil
test
compound
show
depend
substitu
blactam
ring
presenc
singledoubl
linker
increas
spacer
length
n
n
consider
effect
efficaci
test
compound
potent
test
compound
viz
select
age
inhibit
data
determin
ic
valu
defin
minimum
concentr
requir
growth
inhibit
compound
exhibit
ic
valu
lm
respect
shown
tabl
doserespons
curv
depict
fig
potent
compound
evalu
cytotox
hela
cell
result
cytotox
test
consist
show
viabil
compar
untreat
dmsotreat
cell
passag
cell
also
test
bleomycin
doxorubicin
concentr
positit
control
toxic
also
carri
assay
three
independ
day
multipl
trial
experi
compound
consist
show
compar
toxic
untreat
dmsotreat
hela
cell
test
lm
present
commun
describ
synthesi
monoand
blactamisatin
conjug
along
preliminari
vitro
evalu
vaginali
lm
synthes
scaffold
shown
prefer
ptolyl
substitu
blactam
ring
good
activ
potent
noncytotox
compound
exhibit
ic
lm
respect
howev
exact
inhibit
site
blactam
isatin
respons
activ
conjug
still
uncertain
studi
current
underway
